PATH (EIN 91-1157127) - Programs & Services

Program 1 [2020]
GLOBAL HEALTH PROGRAMS: PATH'S GLOBAL HEALTH PROGRAMS DIVISION IS RESPONSIBLE FOR PATH'S SCIENTIFIC EXPERTISE IN MALARIA AND NEGLECTED TROPICAL DISEASES; HIV AND TUBERCULOSIS; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; AND NONCOMMUNICABLE DISEASES. THE DIVISION ALSO OVERSEES PATH'S WORK IN HEALTH SYSTEMS INNOVATION AND DELIVERY, AND MANAGES OUR COUNTRY OFFICES.(CONTINUED ON SCHEDULE O)MALARIA AND NEGLECTED TROPICAL DISEASESPATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS ACROSS THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR MALARIA AND NEGLECTED TROPICAL DISEASES PROGRAM INCLUDES MORE THAN 100 PATH STAFF MEMBERS IN MORE THAN TEN COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DESIGNING NEW STRATEGIES AND DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. PATH-PIONEERED APPROACHES HAVE CONTRIBUTED TO REMARKABLE PROGRESS IN MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2020, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA TOWARD THEIR MALARIA ELIMINATION GOALS. MACEPA'S WORK INCLUDED EVALUATING THE LATEST, MOST SENSITIVE DIAGNOSTIC TESTS; ESTABLISHING RAPID REPORTING SYSTEMS; AND CONTINUING TO SUPPORT POPULATION-WIDE, DRUG-BASED STRATEGIES SUCH AS MASS DRUG ADMINISTRATION. WITH A NEW GRANT FROM THE BILL & MELINDA GATES FOUNDATION, MACEPA BEGAN IDENTIFYING OPPORTUNITIES IN ADDITIONAL HIGH-MALARIA-BURDEN GEOGRAPHIES SUCH AS THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), MALAWI, MALI, AND NIGERIA.PATH WAS ALSO AWARDED AN ADD-ON TO OUR PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES (PAMO), FUNDED BY THE US PRESIDENT'S MALARIA INITIATIVE (PMI). CALLED PAMO PLUS, THE PROJECT CONTINUES ITS PREDECESSOR'S MISSION OF ASSISTING THE GOVERNMENT OF ZAMBIA TO ELIMINATE MALARIA WITHIN ITS BORDERS. IN 2020, PAMO PROVIDED TECHNICAL SUPPORT AND MENTORSHIP TO MORE THAN 2,000 HEALTH CARE PROVIDERS AND TRAINED 1,098 COMMUNITY HEALTH WORKERS AND THEIR 272 SUPERVISORS IN COMMUNITY-LEVEL CASE MANAGEMENT AND SURVEILLANCE. PAMO/PAMO PLUS ALSO SUPPORTED THE DISTRIBUTION OF 122,602 INSECTICIDE-TREATED BEDNETS, ORGANIZED SOCIAL BEHAVIOR CHANGE ACTIVITIES (INCLUDING IN SCHOOLS), AND PROVIDED TECHNICAL AND MATERIAL SUPPORT FOR DATA QUALITY AUDITS IN HEALTH FACILITIES.PATH CONTINUED TO EVALUATE NEW VECTOR CONTROL TOOLS IN 2020 WITH OUR PARTNERS UNDER PMI VECTORLINK, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT'S (USAID'S) FLAGSHIP MALARIA VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT FUNDED BY UNITAID AND THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA, WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. IN ZAMBIA, PATH LED THE DESIGN AND IMPLEMENTATION OF LABORATORY AND FIELD ACTIVITIES TO TEST ANOTHER NEW TOOL FOR MALARIA VECTOR CONTROL, THE ATTRACTIVE TARGETED SUGAR BAIT (ATSB); WE ALSO COORDINATED PARTNERS WORKING ON ATSB RESEARCH IN KENYA, MALI, AND ZAMBIA, TOGETHER WITH ISRAEL-BASED MANUFACTURER WESTHAM LTD. AND UK-BASED FUNDER INNOVATIVE VECTOR CONTROL CONSORTIUM. IN ADDITION, PATH LED A USAID INITIATIVE TO SUPPORT US GOVERNMENT INVESTMENTS IN MALARIA OPERATIONAL RESEARCH AND PROGRAM EVALUATION. UNDER THE PMI INSIGHTS PROJECT, PATH COORDINATED THE WORK OF SEVERAL PARTNERS TO STRENGTHEN POLICIES, STRATEGIES, AND GUIDELINES FOR MALARIA CONTROL AND ELIMINATION INTERVENTIONS. IN SENEGAL AND DRC, PATH BEGAN WORK TO INTEGRATE THE DATA VISUALIZATION DASHBOARDS OF THE NATIONAL EMERGENCY OPERATIONS CENTERS AND NATIONAL MALARIA CONTROL PROGRAMS AND DEVELOP IN-COUNTRY CAPACITY FOR DATA USE. THESE EFFORTS HELPED BOTH COUNTRIES RESPOND TO COVID-19 AND MITIGATE THE VIRUS' IMPACT ON MALARIA CONTROL AND ELIMINATION. PATH AND A PRIVATE-SECTOR TECHNOLOGY PARTNER, BLUESQUARE, SUPPORTED THE DRC MINISTRY OF HEALTH (MOH) TO STRENGTHEN COVID-19 CASE TRACKING AND CONTACT TRACING.AT THE ONSET OF COVID-19, THE PATH LABORATORY TEAM IN ZAMBIA PIVOTED FROM MALARIA TO WHOLE GENOME SEQUENCING OF SARS-COV-2 (THE VIRUS RESPONSIBLE FOR COVID-19) THROUGH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION AND IN COLLABORATION WITH THE UNIVERSITY OF ZAMBIA SCHOOL OF VETERINARY MEDICINE. THE LABORATORY'S WORK ENABLED IDENTIFICATION OF THE BETA (B.1.351) VARIANT OF CONCERN IN ZAMBIA, WHICH WAS ASSOCIATED WITH A MAJOR SECOND WAVE OF COVID-19 IN THE COUNTRY. THE LABORATORY'S WORK ALSO LED TO ESTABLISHMENT OF A NATIONAL SPECIMEN COLLECTION SYSTEM THROUGH THE ZAMBIA NATIONAL PUBLIC HEALTH INSTITUTE.THE VIVACCESS PROJECT, WHICH FOCUSES ON RADICAL CURE (ELIMINATION OF DORMANT LIVER-STAGE PARASITES) OF PLASMODIUM VIVAX MALARIA, CONTINUED TO SUPPORT INTRODUCTION OF G6PD TESTS AND OTHER RADICAL CURE PRODUCTS IN BRAZIL, CAMBODIA, COLOMBIA, ETHIOPIA, INDIA, LAOS, MYANMAR, PERU, THAILAND, AND VIETNAM. VIVACCESS ENGAGED WITH NORMATIVE POLICY BODIES SUCH AS THE WORLD HEALTH ORGANIZATION (WHO), PROMOTED MULTISTAKEHOLDER DISCUSSIONS THROUGH REGIONAL AND GLOBAL EVENTS, AND MUCH MORE. (ADDITIONAL WORK IN MALARIA IS COVERED IN THE CENTER FOR VACCINE INNOVATION AND ACCESS SECTION.)PATH'S EFFORTS TO ELIMINATE NEGLECTED TROPICAL DISEASES CONTINUED IN 2020 IN THE DRC, WHERE WE WORKED TO COMBAT HUMAN AFRICAN TRYPANOSOMIASIS (HAT, OR "SLEEPING SICKNESS") IN COLLABORATION WITH THE COUNTRY'S NATIONAL PROGRAM FOR THE CONTROL OF HAT (PNLTHA). WITH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION, PATH PROVIDED LOGISTICAL AND OPERATIONAL SUPPORT TO THE PNLTHA IN ACTIVE AND PASSIVE CASE DETECTION AND VECTOR CONTROL. WE ALSO SUPPORTED ADVOCACY, SENSITIZATION, AND PROMOTION ACTIVITIES TO STRENGTHEN HAT ELIMINATION EFFORTS AT THE NATIONAL, PROVINCIAL, AND COMMUNITY LEVELS. IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE AT THE NATIONAL, STATE, AND SUB-STATE LEVELS. IN THE STATE OF UTTAR PRADESH, WE HELPED ENSURE TRANSMISSION OF VISCERAL LEISHMANIASIS STAYED AT OR BELOW ELIMINATION LEVEL IN ENDEMIC DISTRICTS THROUGH HIGH-QUALITY SURVEILLANCE, ACTIVE CASE DETECTION, AND VECTOR CONTROL. PATH ALSO PROVIDED TECHNICAL ASSISTANCE FOR LYMPHATIC FILARIASIS (ELEPHANTIASIS) ELIMINATION THROUGH MASS DRUG ADMINISTRATION AND HELPED ESTABLISH A TECHNICAL SUPPORT UNIT FOR DENGUE-CHIKUNGUNYA CONTROL AND MALARIA ELIMINATION. HIV AND TUBERCULOSISPATH'S HIV AND TUBERCULOSIS (TB) PROGRAMMING REACHES GENERAL POPULATIONS AS WELL AS KEY POPULATIONS AFFECTED BY HIV/TB.IN 2020, AS THE COVID-19 RESPONSE HINDERED ACCESS TO HEALTH FACILITIES IN MANY COUNTRIES, PATH MOVED RAPIDLY TO MINIMIZE THE IMPACT ON HIV AND TB SERVICES. PATH USED AN APPROACH OF PROTECT-MITIGATE-SUPPORT: UNDER THE "PROTECT" PILLAR, WE EQUIPPED AND TRAINED FRONTLINE HEALTH CARE PROVIDERS TO TRIAGE AND DELIVER SERVICES TO PEOPLE WITH COVID-19 EXPOSURE OR SYMPTOMS. UNDER THE "MITIGATE" PILLAR, WE ADAPTED WHERE AND HOW HIV AND TB SERVICES WERE OFFERED, SHIFTING TOWARD VIRTUAL, COMMUNITY, AND PRIVATE-SECTOR DELIVERY MODALITIES AND MULTI-MONTH DRUG DISPENSING TO REDUCE THE NEED FOR CLINIC VISITS. UNDER THE "SUPPORT" PILLAR, WE USED EXISTING HIV AND TB PLATFORMS TO DISSEMINATE INFORMATION ON COVID-19, AND WE ADAPTED TB SCREENING PROTOCOLS TO INCLUDE SCREENING AND TRIAGE FOR COVID-19 (AND VICE VERSA). IN THE DRC, UNDER THE USAID-FUNDED INTEGRATED HIV/AIDS PROJECT, PATH INTRODUCED ASSISTED HIV SELF-TESTING (HIVST) VIA PHARMACISTS, ALTERNATIVE MEDICINE PROVIDERS, AND COMMUNITY HEALTH WORKERS. WE TESTED APPROXIMATELY 180,000 PEOPLE, ENROLLED AROUND 12,400 NEWLY IDENTIFIED PEOPLE LIVING WITH HIV (PLHIV) ON ANTIRETROVIRAL THERAPY (ART), AND SUPPORTED MORE THAN 43,800 INDIVIDUALS TO CONTINUE TREATMENT. IN WESTERN KENYA, UNDER THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF-FUNDED AFYA ZIWANI PROJECT, PATH EVOLVED OUR APPROACH, PARTICULARLY FOR HIV-NEGATIVE AGYW. THE PROJECT CREATED WHATSAPP-BASED VIRTUAL SAFE SPACES AND MOBILE, HOME-BASED SAFE SPACES TO ENSURE AGYW CONTINUED TO RECEIVE INFORMATION, COUNSELING, AND OTHER SERVICES DURING THE COVID-19 PANDEMIC; WE ALSO USED THESE SPACES TO DISSEMINATE INFORMATION ON COVID-19. THE PROJECT HOME-DELIVERED APPROXIMATELY 800 HIV PRE-EXPOSURE PROPHYLAXIS REFILLS AND MORE THAN 8,000 HIVST KITS FOR AGYW, WITH NO HIV-POSITIVE RESULTS. ACROSS ALL POPULATION GROUPS, AFYA ZIWANI TESTED MORE THAN 140,000 PEOPLE FOR HIV, LINKED ABOUT 3,500 NEWLY IDENTIFIED PLHIV TO ART, AND SUPPORTED A COHORT OF 25,600 PEOPLE ON TREATMENT.
Geographies
Not indicated
Dates
Jan 1, 2020 – Dec 31, 2020
Source
990
No causes provided
No populations provided
–
$115M
Program 2 [2020]
ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE. IN RESPONSE TO THE COVID-19 PANDEMIC, PATH MOBILIZED QUICKLY TO DEPLOY OUR END-TO-END IMMUNIZATION EXPERTISE. WE PROVIDED POLICY AND FINANCIAL ADVICE TO GAVI ON DESIGN OF THE COVAX FACILITY WITH THE GOAL OF EQUITABLE COVID-19 VACCINE ACCESS AND DELIVERY WORLDWIDE. WE SECURED INITIAL FUNDING TO ADVANCE A LOW-COST COVID-19 VACCINE CANDIDATE (NDV-HXP-S) BASED ON TECHNOLOGIES DEVELOPED BY THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI AND THE UNIVERSITY OF TEXAS AT AUSTIN THAT IS TARGETED FOR EMERGING COUNTRY VACCINE MANUFACTURERS. ACROSS THE COVID-19 VACCINE DEVELOPMENT ECOSYSTEM, WE SUPPORTED VACCINE DEVELOPMENT AND CLINICAL SITE READINESS; PROVIDED CHEMISTRY, MANUFACTURING, AND CONTROL EXPERTISE TO MANUFACTURERS; AND LENT OUR CLINICAL, TECHNICAL, AND REGULATORY EXPERTISE TO DEVELOPERS AND COVID-19 CONSORTIA.IN 2020, PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. THE NOVEL ORAL POLIO VACCINE AGAINST TYPE 2 POLIOVIRUS (NOPV2) ACHIEVED A MAJOR MILESTONE WHEN IT BECAME THE FIRST VACCINE TO RECEIVE A WHO EMERGENCY USE LISTING (EUL). AS THE CONVENOR OF THE NOPV2 CONSORTIUM, PATH CONTRIBUTED KEY EVIDENCE AND SUPPORTED THE MANUFACTURER'S SUCCESSFUL EUL APPLICATION. THROUGHOUT 2020, PATH AND OUR COUNTRY PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. WRAPPING UP A REMARKABLE 17-YEAR GLOBAL PARTNERSHIP, PATH COMPLETED TWO STUDIES EXAMINING JE VACCINE DURATION OF PROTECTION AND CO-ADMINISTRATION AND FINALIZED A SUITE OF MATERIALS OUTLINING THE LESSONS AND STORY OF JE VACCINATION EFFORTS. ALSO IN 2020, WE CONTINUED A PIVOTAL, PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE. THE VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE ALSO CONTRIBUTED TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL "DEFEATING MENINGITIS BY 2030" INITIATIVE, WHICH CULMINATED IN WORLD HEALTH ASSEMBLY ADOPTION OF THE FIRST-EVER RESOLUTION ON MENINGITIS PREVENTION AND CONTROL AND ENDORSEMENT OF A GLOBAL ROAD MAP TO DEFEAT MENINGITIS.TO PREVENT MALARIA, PATH ACCELERATED THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. FOR EXAMPLE, WE WORKED WITH WHO AND OTHER PARTNERS, INCLUDING THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI, TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. WE ALSO CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO FURTHER AID MALARIA ELIMINATION EFFORTS BY STRETCHING LIMITED VACCINE SUPPLIES AND PROTECTING AS MANY PEOPLE AS POSSIBLE. ADDITIONALLY, WORK CONTINUED ON EFFORTS TO IDENTIFY IMMUNE CORRELATES OF PROTECTION AND STUDY THE USE OF MONOCLONAL ANTIBODIES TO COMBAT MALARIA. IN 2020, PATH RECEIVED A FIVE-YEAR GRANT FROM USAID TO ADVANCE PRE-ERYTHROCYTIC, BLOOD-STAGE, AND COMBINATION MALARIA VACCINE CANDIDATE APPROACHES.THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE. A MAJOR FOCUS OF 2020 WAS A CAMPAIGN TO MAINTAIN CHILD HEALTH INVESTMENTS DURING THE COVID-19 PANDEMIC, INCLUDING STEADY ACCESS TO ESSENTIAL MEDICINES AND ROUTINE IMMUNIZATION. IN ONGOING EFFORTS TO SUPPORT LOCAL VACCINE PRODUCTION, PATH SUPPORTED VIETNAM-BASED MANUFACTURER POLYVAC TO COMPLETE CLINICAL TRIALS FOR THE LIQUID FORMULATION OF ROTAVIN VACCINE. OUR PHASE 3 STUDY FOUND THAT ROTAVIN IS AS SAFE AND IMMUNOGENIC AS THE CURRENTLY LICENSED FROZEN FORMULATION, ROTAVIN-M1. WE COMPLETED THE CLINICAL PHASE OF A PHASE 1 STUDY IN THE UNITED STATES OF A NOVEL, INJECTABLE SUBUNIT SHIGELLA VACCINE CANDIDATE AND INITIATED FOLLOW-ON EXPLORATORY IMMUNOLOGY ANALYSES USING SAMPLES FROM THE STUDY. AND WE CONTINUED TO HELP INTRODUCE AND ADVANCE ACCESS TO CURRENTLY AVAILABLE ROTAVIRUS VACCINES.PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, THE LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. WE SUPPORTED INVENTPRISE, A BIOTECHNOLOGY COMPANY, AS IT WORKS TO DEVELOP A MULTIVALENT, CONJUGATE VACCINE FOR LOW- AND MIDDLE-INCOME COUNTRIES. THE INTENDED RECIPIENTS ARE PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES. WITH OUR SUPPORT, THE GOVERNMENTS OF MALAWI AND NEPAL MADE THE DECISION TO INTRODUCE TCV AND SUCCESSFULLY APPLIED FOR ASSISTANCE FROM GAVI. PATH ALSO WORKED WITH THE GOVERNMENT OF KENYA ON ITS DECISION TO INTRODUCE TCV AND BEGIN PLANNING. TO ACCOUNT FOR CHALLENGES BROUGHT ON BY THE COVID-19 PANDEMIC, WE HELPED THE GOVERNMENTS OF LIBERIA, PAKISTAN, AND ZIMBABWE ADJUST THEIR TCV CAMPAIGNS.ALSO IN 2020, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO ANALYZE EVIDENCE ON SINGLE-DOSE HPV VACCINATION. FOR COUNTRIES WITH FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO INTRODUCTION, A SINGLE-DOSE REGIMEN COULD BE TRANSFORMATIVE. AMONG OTHER ASSISTANCE, OUR GLOBAL TEAM AND PARTNERS HELPED GAVI-ELIGIBLE COUNTRIES RESPOND TO THE COVID-19 PANDEMIC BY PIVOTING HPV VACCINATION PROGRAMS TO REACH OUT-OF-SCHOOL GIRLS.DRUG DEVELOPMENTTHROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE-FROM EARLY RESEARCH TO INTRODUCTION.IN 2020, WE COMPLETED A PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL OF IOWH032, A NOVEL ANTISECRETORY DRUG CANDIDATE FOR THE TREATMENT OF CHOLERA. WHILE IOWH032 WAS NOT EFFICACIOUS IN THIS STUDY, WE LEARNED IMPORTANT LESSONS FOR FUTURE DRUG TRIALS AND CONTINUE TO EXPLORE OTHER USES OF THIS COMPOUND, INCLUDING FOR TREATMENT OF COVID-19, CYSTIC FIBROSIS, AND POTENTIALLY OTHER INDICATIONS.IN ADDITION, WE CONTINUED OUR WORK ON DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE TREATMENT IS AVAILABLE. WE CONDUCTED KEY PRECLINICAL STUDIES AND SELECTED A COMPOUND FOR LARGE-ANIMAL EFFICACY TRIALS.THE DIARRHEA INNOVATIONS GROUP, AN INTERNATIONAL NETWORK OF CHILD HEALTH STAKEHOLDERS HOUSED WITHIN AND CO-CHAIRED BY PATH, CONTINUED TO ADVOCATE IN SUPPORT OF A LIFESAVING TREATMENT FOR DIARRHEA IN CHILDREN: THE USE OF CO-PACKAGED ORAL REHYDRATION SOLUTION AND ZINC, RECOGNIZED BY WHO AS AN ESSENTIAL MEDICINE. INCREASED ACCESS TO THIS TREATMENT COULD ACCELERATE PROGRESS TOWARD CHILD HEALTH GOALS.WITH OUR MANUFACTURING PARTNER QUANSYS BIOSCIENCES, WE MOVED TOWARD COMMERCIALIZATION OF A NEW TOOL FOR ASSESSING ENVIRONMENTAL ENTERIC DYSFUNCTION-AN INTESTINAL DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE.
Geographies
Not indicated
Dates
Jan 1, 2020 – Dec 31, 2020
Source
990
No causes provided
No populations provided
–
$92.6M
Program 3 [2020]
TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION: PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION (TAMI) DIVISION IS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT MEDICAL DEVICES, HEALTH TECHNOLOGIES, DIAGNOSTICS, AND IN-COUNTRY "IMPACT LABS" THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. TAMI ALSO MANAGES PATH'S WORK IN MARKET DYNAMICS AND DIGITAL AND DATA EXCELLENCE.(CONTINUED ON SCHEDULE O)MEDICAL DEVICES AND HEALTH TECHNOLOGIESTHE MEDICAL DEVICES AND HEALTH TECHNOLOGIES (MDHT) PROGRAM WITHIN TAMI IS PATH'S PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES.MILESTONES IN 2020 INCLUDED BEGINNING THE WORLD'S FIRST FREEZE-PREVENTIVE COLD BOX EVALUATION IN NEPAL; COMPLETING A THREE-YEAR INTRODUCTION AND SCALE-UP OF 7.1 PERCENT CHLORHEXIDINE FOR UMBILICAL CORD CARE IN FRANCOPHONE WEST AFRICA; RECEIVING REGULATORY APPROVAL IN GHANA AND KENYA FOR THE ELLAVI UTERINE BALLOON TAMPONADE-A PATH-DEVELOPED, LIFESAVING MEDICAL DEVICE FOR POSTPARTUM HEMORRHAGE; AND SERVING AS A KEY PARTNER ON THE GAVI-LED VACCINE INNOVATION PRIORITIZATION STRATEGY.MDHT ALSO ADDRESSED THE COVID-19 PANDEMIC: ONE EFFORT AIMED TO ACCELERATE EQUITABLE GLOBAL ACCESS TO COVID-19 VACCINES THROUGH A COLLABORATION WITH UNICEF AND THE COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS. WORKING CLOSELY WITH PATH'S CENTER FOR VACCINE INNOVATION AND ACCESS, MDHT ASSESSED THE GLOBAL SUPPLY CHAIN FOR VACCINE COMPONENTS, VACCINE MANUFACTURING CAPACITY, SYRINGE AVAILABILITY, AND COLD CHAIN AND ULTRA-COLD CHAIN CAPACITY. WE ALSO ASSESSED COVID-19 VACCINE COLLATERAL MATERIALS AND INFORMATION-FOR EXAMPLE, NEW PACKAGING AND DELIVERY TECHNOLOGIES, WHO LABELING GUIDELINES, AND E-LEARNING MODULES.MDHT'S LIVING LABS INITIATIVE USED HUMAN-CENTERED DESIGN METHODS IN KENYA AND ZAMBIA TO IDENTIFY CHALLENGES AND PROPOSE SOLUTIONS TO THE MANY OBSTACLES IMMUNIZATION WORKERS FACE. IN KENYA, THE LIVING LABS TEAM ENGAGED HEALTH CARE WORKERS TO IDENTIFY CHALLENGES IN MANAGING POSTPARTUM HEMORRHAGE AND PRIORITIZE SOLUTIONS FOR GOVERNMENT RESPONSE. IN 2020, MDHT STAFF PRODUCED NINE PEER-REVIEWED JOURNAL ARTICLES AND RESEARCH REPORTS ON TOPICS RANGING FROM FREEZE-DRIED TABLETS FOR ORAL VACCINE DELIVERY TO CHLORHEXIDINE FOR FACILITY-BASED UMBILICAL CORD CARE.LAST, A CONSULTANT HIRED BY THE PATH SOUTH AFRICA IMPACT LAB WORKED CLOSELY WITH THE GLOBAL HEALTH INNOVATION ACCELERATOR/SOUTH AFRICAN MEDICAL RESEARCH COUNCIL ON A MEDICAL DEVICE LANDSCAPING ACTIVITY DESIGNED TO ACCELERATE PRODUCTION AND INTRODUCTION OF NOVEL HEALTH TECHNOLOGIES.DIAGNOSTICSPATH'S DIAGNOSTICS PROGRAM ADVANCES EQUITABLE AND SUSTAINABLE ACCESS TO AFFORDABLE, QUALITY-ASSURED DIAGNOSTICS FOR BETTER DIAGNOSIS AND TREATMENT IN LOW-RESOURCE SETTINGS.IN 2020, OUR PIONEERING WORK INCLUDED DEVELOPING, VALIDATING, EVALUATING, AND COMMERCIALIZING TESTS, REFERENCE ASSAYS, AND TOOLS; CONDUCTING LABORATORY PERFORMANCE EVALUATIONS AND CLINICAL STUDIES TO INFORM PATIENT CARE; FACILITATING A G6PD OPERATIONAL RESEARCH COMMUNITY OF PRACTICE; AND PUBLISHING 15 PEER-REVIEWED JOURNAL ARTICLES.THE DIAGNOSTICS TEAM RAPIDLY RESPONDED TO THE GLOBAL COVID-19 PANDEMIC WITH LABORATORY-BASED ACTIVITIES TO SUPPORT DIAGNOSTIC DEVELOPERS. THIS INCLUDED CREATING A BIOREPOSITORY OF QUALIFIED COVID-19 CLINICAL SAMPLES TO ACCELERATE THE DEVELOPMENT AND VALIDATION OF NEW COVID-19 DIAGNOSTIC TESTS (PROVIDED FREE OF CHARGE TO DEVELOPERS INTENDING TO SUPPLY GLOBAL MARKETS); CREATING FIVE DIGITAL, INTERACTIVE COVID-19 DIAGNOSTICS DASHBOARDS THAT AGGREGATE AND VISUALIZE PUBLICLY AVAILABLE INFORMATION ON THE DEVELOPMENT, SUPPLY, REGULATORY APPROVAL, AND PERFORMANCE OF COVID-19 DIAGNOSTIC TESTS (TO SUPPORT PRODUCT SELECTION AND PROCUREMENT DECISIONS WORLDWIDE); CONDUCTING IN-HOUSE EVALUATIONS OF NEW COMMERCIAL RAPID DIAGNOSTIC TESTS TO VERIFY PERFORMANCE CLAIMS AND FIT-FOR-PURPOSE IN INTERNATIONAL SETTINGS; ENSURING THE QUALITY OF COVID-19 RAPID DIAGNOSTIC TESTS WITH A BENCHMARKING PANEL THAT ENABLES UNBIASED, COMPARATIVE EVALUATIONS BETWEEN COVID-19 TESTS; SUPPORTING THE NATIONAL RESPONSE IN INDONESIA, MALAWI, NEPAL, AND PAKISTAN WITH ENVIRONMENTAL SURVEILLANCE DATA COLLECTION PROJECTS TO DETECT AND QUANTIFY THE PRESENCE OF SARS-COV-2 IN IMPACTED WASTEWATER; AND ENSURING THAT COVID-19 POINT-OF-CARE TESTS ARE SUITABLE FOR CLINICAL AND OPERATIONAL STUDIES IN BRAZIL.IN PARTNERSHIP WITH THE UNIVERSITY OF QUEENSLAND, THE DIAGNOSTICS TEAM SUPPORTED THE COMMERCIALIZATION OF CUSTOM MALARIA PROTEINS TO FACILITATE PERFORMANCE BENCHMARKING OF RAPID, ACCURATE, AND SPECIES-SPECIFIC MALARIA DIAGNOSTIC TESTS.THE TEAM ALSO SUBMITTED REGULATORY DOSSIERS FOR THE SD BIOSENSOR STANDARD G6PD TEST, WHICH GUIDES THE TREATMENT OF PLASMODIUM VIVAX MALARIA, TO THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION, THE US FOOD AND DRUG ADMINISTRATION, AND WHO FOR PREQUALIFICATION. IN 2020, NEARLY 75,000 OF THESE TESTS WERE DISTRIBUTED TO 30 COUNTRIES.INDIA IMPACT LABINDIA HAS A RICH INNOVATION ECOSYSTEM WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS FOCUSED ON DEVELOPING PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE. PATH'S INDIA IMPACT LAB, A PARTNERSHIP WITH TATA TRUSTS AND THE INDIAN INSTITUTE OF TECHNOLOGY DELHI, IS A PLATFORM TO ENABLE LATE-STAGE MEDICAL TECHNOLOGY INNOVATIONS TO ACHIEVE MARKET ENTRY, ADOPTION, AND SCALE. THE IMPACT LAB PARTNERS WITH TOP INDIAN TECHNOLOGY AND BUSINESS INCUBATORS IN THE LIFE SCIENCE AND HEALTH CARE INDUSTRIES. IN 2020, THE IMPACT LAB LED PATH'S PARTNERSHIP WITH THE CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS, A PUBLIC-PRIVATE INITIATIVE THAT LAUNCHED THE COVID-19 INNOVATIONS DEPLOYMENT ACCELERATOR (C-CIDA) IN MARCH 2020. C-CIDA HELPS FAST-TRACK INNOVATIONS IN SCREENING, DIAGNOSIS, TREATMENT, MONITORING, CARE, AND MANAGEMENT OF COVID-19. THE IMPACT LAB CONTINUED TO SUPPORT THE MARKET ACCESS PROGRAM OF THE INDIA NATIONAL HEALTH AUTHORITY AND PARTNERED WITH XYNTEO INDIA ON PROJECT TEJ, AN INITIATIVE OF THE TELANGANA STATE GOVERNMENT AND MEDTECH CONNECT TO ACCELERATE INDIAN MEDICAL TECHNOLOGY INNOVATIONS. IN ADDITION, THE IMPACT LAB MANAGED A PIPELINE OF INNOVATIONS BEING EXPLORED FOR INTEGRATION WITH PRIMARY HEALTH CARE, IMMUNIZATION, NUTRITION, TB, COVID-19, FAMILY PLANNING, AND REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH PROGRAMS.THE IMPACT LAB ALSO CONTINUED ITS CROSSCUTTING SUPPORT OF VARIOUS PROGRAMS AT PATH; FOR EXAMPLE, EVALUATING LOW-FIELD MAGNETIC RESONANCE IMAGING, IMPROVING ACCESS TO COVID-19 TESTING IN INDIA THROUGH SYSTEM STRENGTHENING, EVALUATING A BLOW-FILL-SEAL ORAL VACCINE RECONSTITUTION DELIVERY SYSTEM, AND MARKET RESEARCH FOR NEWBORN SCREENING AND G6PD TESTING IN THE PRIVATE HEALTH SECTOR. MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM WORKS TO IMPROVE HEALTH EQUITY AND HEALTH OUTCOMES BY EVALUATING MARKETS, ASSESSING ROOT CAUSES OF LIMITED ACCESS TO HEALTH CARE PRODUCTS AND SERVICES, AND DESIGNING AND IMPLEMENTING MARKET-BASED INTERVENTIONS TO INCREASE ACCESS. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT/INTRODUCTION AND HEALTH SYSTEMS STRENGTHENING AND IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, AND PATH'S COUNTRY PROGRAMS.IN 2020, OUR WORK WAS FOCUSED PRIMARILY ON IMPROVING ACCESS TO MEDICAL OXYGEN AND RELATED RESPIRATORY CARE PRODUCTS FOR COVID-19 TREATMENT AS WELL AS MALARIA DRUGS AND DIAGNOSTICS.CENTER OF DIGITAL AND DATA EXCELLENCEPATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH EQUITY. IN 2020, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE (CODE) APPLIED ITS EXPERTISE TO ACCELERATE COUNTRY-LED DIGITAL HEALTH, DEEPEN THE USE OF DATA, AND SUPPORT THE GLOBAL COVID-19 RESPONSE. KEY ACCOMPLISHMENTS INCLUDED CO-AUTHORING WHO'S DIGITAL IMPLEMENTATION INVESTMENT GUIDE, WHICH OFFERS A SYSTEMIC PROCESS FOR COUNTRIES TO DEVELOP COSTED IMPLEMENTATION PLANS FOR DIGITAL HEALTH. DIGITAL SQUARE, A PATH-LED INITIATIVE, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES. DIGITAL SQUARE LED THE HEALTH DATA SCIENCE EXCHANGE, AN EXPLORATORY EFFORT TO UNDERSTAND HOW THE GREATER COORDINATION OF DATA SCIENCE TOOLS AND APPROACHES COULD IMPROVE HEALTH IMPACT. DIGITAL SQUARE ALSO BEGAN WORK ON MAP & MATCH, A LANDSCAPING ACTIVITY TO IDENTIFY EXISTING NATIONAL-LEVEL SOFTWARE TOOLS AND TECHNOLOGIES THAT CAN BE ADAPTED FOR COVID-19 RESPONSE.
Geographies
Not indicated
Dates
Jan 1, 2020 – Dec 31, 2020
Source
990
No causes provided
No populations provided
–
$32.2M

PATH

PATH

PATH

Overview

Programs

990s

Income Statement

Balance Sheet

How to Apply

Board & Team

Financial Trends

Funders

Grants Received

Giving Insights

Grantees

Grants Given

Overlap

Programs

Program 1 [2020]

Program 2 [2020]

Program 3 [2020]

Programs